Compare AstraZeneca plc (AZN) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Gemini Space Station Inc — how do they compare? AstraZeneca plc trades at $166.65 (market cap $253.13B), while Gemini Space Station Inc trades at $4.39 (market cap $548.72M). The key difference: AstraZeneca plc is far larger — about 461.3× Gemini Space Station Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| AZN | GEMI | |
|---|---|---|
Market Cap | $253.13B | $548.72M |
Sector | Health | Technology |
52-Week High | $209.48 | $32.52 |
52-Week Low | $137.44 | $3.91 |
Enterprise Value | $279.37B | $538.70M |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
GEMI trades at $4.25, down 1.39% on the day, amid a bearish technical signal and weak fundamentals. The company reported significant losses, with a net income margin of -278.9% in 2025, and has missed earnings expectations for three consecutive quarters. Recent news includes a class action lawsuit and a $100 million investment from Winklevoss Capital, creating mixed sentiment.
The outlook remains challenging due to persistent unprofitability and legal risks, though analyst consensus suggests moderate upside with a $5.88 price target. Investment opportunity hinges on the company's ability to leverage new capital for growth, but high execution and regulatory risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
